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Abstract
Background: Klebsiella is one of the Enterobacteriaceae family that causes infections such as pneumonia, urinary tract infections
(UTI), and meningitis. Klebsiella strains are capable of producing enzymes that can degrade the third-generation of cephalosporins
known as broad-spectrum beta-lactamase enzymes. The resistance of Klebsiella strains toβ-lactam antibiotics is related to the pres-
ence of β-lactamase genes.
Methods: In this study, 90 isolates of Klebsiella were isolated from two inpatient and outpatient groups, each of them was 45 isolates,
which were collected from patients with urinary tract infection in educational hospitals of Shahrekord. The isolates were identified
using phenotypic agar diffusion, disc phenotypic confirmation tests, and E-test of extended-spectrum beta-lactamase (ESBL). The
PCR molecular method was used to diagnose and determine the strains containing broad-spectrum β-lactamases.
Results: Thirty (66%) inpatients and 8 (17.8%) outpatients had broad-spectrum β-lactamase enzymes. The frequency of β-lactamase
OXA-10 genes and PER in inpatients were 90% and 33%, respectively and also in outpatients were 50% and 12.5%, respectively.
Conclusions: This study showed that the prevalence of isolated Klebsiella producing broad-spectrum β-lactamases is higher in in-
patients in comparison to outpatients. Therefore, the rapid and accurate identification of bacteria and their resistance genes in
clinical microbiology labs are highly recommended.
Keywords: Klebsiella, Minimum Inhibitory Concentration, Extended Spectrum β-Lactamases, OXA-10, PER Gene
1. Background
Urinary tract infection (UTI) is known as an infection
that affects 150 million people annually and the second
most common infection reported in Iran and the world. It
causes seven million visits by doctors due to UTI each year
(1, 2). Klebsiella pneumoniae and Escherichia coli among the
Enterobacteriaceae family are more likely to be acquired in-
fections and hospital infections than the rest of the family
(3). Klebsiella is an opportunistic organism that causes hos-
pital infection and acquired community infection, such
as septicemia, pneumonia, and urinary tract infections,
soft tissue infections, liver damage, abscess, and menin-
gitis (4). The importance of this bacterium as a human
pathogen is the development of hospital infections and
the involvement of the patients with immunodeficiency or
underlying diseases such as diabetes mellitus and chronic
pulmonary disorders (5).
The emergence of antibiotics such as cephalosporin
and aztreonam and their increased consumption have
led to the emergence of a new group of β-lactamase en-
zymes called broad-spectrum β-lactamases (ESBLs) (6). Al-
though carbapenems are preferred choice for infections
nowadays, unfortunately, many Gram-negative bacteria
with multi-drug resistance (MDR) are also resistant to car-
bapenems (7). The β-lactamase genes are transmitted ver-
tically and horizontally between bacteria. There are more
than 300 sub-groups of ESBLs, which mutations in their
genes led to the production of new β-lactamases capable
of hydrolyzing third-generation cephalosporins and aztre-
onam (8). So far, 340β-lactamase enzymes have been iden-
tified and classified according to the classification of the
ambler to four categories A, B, C, and D, which A, C, and D
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have the active site for serine, while class B requires zinc
ion for its activity, and class D includes a group that is nat-
urally similar to class A and C enzymes, which are the same
as oxacillinase (9).
OXA beta-lactamases are found mainly in Enterobac-
teriaceae and Pseudomonas aeruginosa and belong to the
molecular D class. They are responsible for resistance to
ampicillin and cefalotin and are characterized by high hy-
drolytic activity against oxacillin and flucloxacillin, weakly
inhibited by clavulanic acid and are often resistant to cef-
tazidime and low resistant to carbapenems (10, 11). For the
first time, PER gene in a clinical specimen of a patient in
a French hospital has been reported from P. aeruginosa.
PERβ-lactamases have high resistance to ceftazidime, cefo-
taxime, and monobactam; additionally, they can cause low
resistance to carbapenems and cephamycin. They are well
controlled by clavulanic acid and tazobactam (12). There-
fore, rapid detection and identification of these resistant
strains help to adopt an appropriate and concise treatment
and helps to control infection and prevent the further de-
velopment of them (13-15) It is, therefore, necessary to de-
termine the pattern of antibiotic resistance of bacteria in
each region. Considering the prevalence of ESBLs in Kleb-
siella in every region makes possible for the clinicians to
choose effective antibiotics in order to quickly eradicate in-
fections caused by these bacteria.
2. Objectives
The aim of this study was to determineβ-lactamase en-
zymes, minimum inhibitory concentration (MIC) for cef-
tazidime, cefotaxime, and ceftriaxone and determination
of the frequency of β-lactamase OXA-10 and PER genes in
Klebsiella strains isolated from UTIs.
3. Methods
3.1. Bacterial Isolates
In this descriptive-analytical study, 90 isolates of Kleb-
siella were collected from patients with UTI in two inpa-
tient (n = 45) and outpatient (n = 45) groups in 2016. In-
patient samples included those taken from patients who
had been diagnosed with UTI 48 - 72 hours after being
admitted to the hospital. Outpatient samples were also
prepared from the patients who had not a hospital stay
in the past month. Klebsiella isolates were recognized
through microscopy, Gram stain, culture, and biochemi-
cal tests. Eosin methylene blue media, MacConkey agar,
and Blood agar (Merck Co., Germany) were used for cul-
ture. Uropathogenic microorganisms were known via phe-
notypic tests of exact culture and typical phenotypic struc-
tures. Bacterial isolates were then recognized by Gram
staining and a series of typical biochemical tests.
3.2. Antimicrobial Susceptibility Testing
An antibiotic susceptibility test was done by the disk
diffusion method (Kirby Bauer), according to the clinical
laboratory standards institute criteria (CLSI) on Mueller-
Hinton agar (Merck, Germany). The discs of antibacterial
used in this study contained amikacin (30 ug), ceftazidime
(30 ug), ciprofloxacin (5 ug), cefazolin (30 ug), imipenem
(10 ug), co-trimoxazole (25 ug), and nalidixic acid (30 ug)
by disc diffusion method.
3.3. Minimum Inhibitory Concentration and Phenotypic Confir-
matory Tests
To determine the production of broad-spectrum
β-lactamase enzymes, phenotypic confirmatory tests
were performed, including ceftazidime (30 ug) and cef-
tazidime/clavulanic acid (10 ug) disc. If the diameter
of halo ceftazidime/clavulanic acid was greater than
5mm in comparison to ceftazidime, ESBL production was
confirmed. Then MIC for ceftazidime, cefotaxime, and cef-
triaxone was determined by E-test tape method. The E-test
has been reported to be a simple and correct different
method for determining the antimicrobial susceptibility
of different microorganisms. The MIC for ceftazidime,
cefotaxime, and ceftriaxone was determined according
to the general committee’s clinical laboratory standard
criteria for phenotypic ESBL-producing Klebsiella isolates
using the E-test strip (16, 17).
3.4. DNA Extraction and PCR
The plasmid DNA was extracted by using a fermentas
plasmid kit. The PCR test was performed using specific
primers for OXA-10 and PER genes (18). The 16srRNA gene
was also used for internal control. Positive PCR control is
Klebsiella pneumoniae ATCC 700603 (19). The sequence of
the primers was shown in Table 1.
Table 1. The Sequence of the Primers Used in This Study
Primers Sequences Genes Size (bp)
OXA-10 blaOXA-10 720
F GTCTTTCGAGTACGGCATTA
R ATTTTCTTAGCGGCAACTTAC
PER blaPER 927
F ATGAATGTCATCACAAAATG
R TCAATCCGGACTCACT
16SrRNA Internal 420
F AGGCCTTCGGGTTGTAAAGT
R ACCTCCAAGTCGACATCGTT
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4. Results
In this study, from 45 outpatients, 18 were female and
27 were male. Of the 45 inpatients, 22 were female and
23 were male. In terms of age, the minimum age was 6
years and the maximum age was 64 years. From 90 iso-
lates of Klebsiella, 82 isolates belonged to K. pneumoniae
species and 8 isolates to K. oxytokka species. In this study,
out of 45 inpatient samples, 40 isolates of K. pneumoniae
and 5 isolates of K. oxytokka were isolated. Also, 42 isolates
of K. pneumoniae and 3 isolates of K. oxytokka were gath-
ered from outpatient infections. The susceptibility pat-
tern of different antibiotics, as well as the percentage of
resistance in inpatients and outpatients, were presented
in Table 2. As shown in Table 2, the highest antibiotic re-
sistance in inpatient and outpatients was related to an-
tibiotic sulfamethoxazole-trimethoprim, which was 86.6%
and 66.7% in the inpatient and outpatient, respectively.
The results indicated that antibiotic resistance was
higher in inpatients compared to outpatients. Also, based
on the results, the lowest antibiotic resistance was found in
amikacin antibiotics in inpatients and outpatients, which
was 6.7% and 2.2%, respectively. Antibiotic resistance pat-
terns based on MIC were provided in Tables 3 - 5. Based on
Fischer’s exact test, P value < 0.001 was considered signif-
icant. The results showed that there was a significant rela-
tionship between increasing the MIC of ceftazidime, cefo-
taxime, and ceftriaxone and Klebsiella strains isolated from
UTI. A confirmatory phenotypic test was used to confirm
the production of broad-spectrum β-lactamase enzymes.
Based on the results of this test, 30 isolates of inpa-
tient samples and 8 isolates of outpatients were positive
for producing of ESBLs. PCR method was used to determine
the frequency of β-lactamase genes. After the completion
of the PCR steps, electrophoresis was applied to agarose
gel to observe and separate the bands. After completion
of electrophoresis, the agarose gel was stained (Figure 1).
Accordingly, the frequency of β-lactamase OXA-10 and PER
genes in Tables 6 and 7 is shown in two groups of inpatient
and outpatient specimens. According to the results, there
was a significant relationship between the presence of β-
lactamase genes in inpatients and outpatients.
5. Discussion
Klebsiella pneumoniae is one of the most important
bacteria that we are witness to the emergence and devel-
opment of resistant strains with MDR in recent decades
due to excessive and incorrect consumption of antibiotics.
Therefore, in such a situation, rapid diagnosis of MDR
strains and the provision of appropriate therapeutic ap-
proach for both the patient and the treatment system is
very important. The release of drug resistance factors
Figure 1. Agarose stained gel; M marker, 1: negative control, 2: positive control of
internal control, 3: positive control of Oxa-10, 4: positive control of PER, 5.6 and 7
samples containing Oxa-10 gene and internal control gene, 8 and 9 samples PER and
internal gene
among Gram-negative bacteria increases the resistance
of these microorganisms to antimicrobial antibiotics, the
persistence of these infections, and the prolongation of
the patient’s therapeutic procedures (20-22).
The present study was carried out to determine the
antibiotic susceptibility pattern on Klebsiella isolates
from urinary tract infections. The highest antibiotic
resistance is in the patients receiving trimethoprim-
sulfamethoxazole antibiotics. The results indicated that
antibiotic resistance was high in inpatients compared to
outpatients. Also, based on the results, the lowest antibi-
otic resistance was found in amikacin antibiotic in the
inpatients and outpatients. Current findings indicated
that antibiotic resistance is higher in inpatients than
outpatients. Saeidi et al., in 2014, conducted an antibiotic
resistance study for ceftriaxone (100%) and ceftazidime
(100%), which was higher than the resistance pattern
in this study for these antibiotics (20). In a study con-
ducted by Eftekhar et al., in 2012, antibiotic resistance
was evaluated to third-generation cephalosporins such
as ceftazidime, ceftriaxone plus other antibiotics such as
amikacin and nitrofurantoin, with 41%, 2%, 37%, 41%, and
49%. The percentage was reported to be similar to the
antibiotic resistance pattern in this study (23).
In a study conducted by Gholipour et al. in Isfahan,
the results of the antibiotic resistance pattern for nalidixic
acid, gentamicin, cefepime, and amikacin were lower than
those reported in this study, which is consistent with our
study for the low resistance to amikacin (24). The con-
firmed phenotypic test results in this study indicated that
66.6% and 17.7% of the isolates were able to produce ESBL
among inpatients and outpatients. According to a study
conducted by Jalalpoor and Mobasherizadeh, in Esfahan in
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Table 2. Antibiotic Susceptibility Pattern of Klebsiella Species
Antibiotics
Inpatient Outpatient
P Value
S I R S I R
Amikacin 34 (75.6) 8 (17.7) 3 (6.7) 41 (91.1) 3 (6.7) 1 (2.2) < 0.001
Ceftazidime 12 (26.6) 3 (6.7) 30 (66.6) 32 (71.1) 5 (11.1) 8 (17.8) < 0.001
Ciprofloxacin 20 (44.4) 10 (22.2) 15 (34.4) 32 (71.1) 4 (8.9) 9 (20) < 0.001
Imipenem 18 (40) 3 (6.7) 24 (53.3) 30 (66.7) 5 (11.1) 10 (22.2) < 0.001
Ceftriaxone 11 (24.4) 2 (4.5) 32 (71.1) 31 (68.8) 2 (4.5) 12 (26.7) < 0.001
Cefotaxime 13 (29) 1 (2.2) 31 (68.8) 30 (66.7) 6 (13.3) 9 (20) < 0.001
Sulfamethoxazole-trimethoprim 4 (9) 2 (4.4) 39 (86.6) 10 (22.2) 5 (11.1) 30 (66.7) < 0.001
Table 3. Antibiotic Resistance Pattern of Ceftriaxone Based on MIC
Group
Ceftriaxone
Totals P Value
S I R
Inpatient 11 2 32 45
< 0.001Outpatient 31 2 12 45
Totals 42 4 44 90
Table 4. Antibiotic Resistance Pattern of Cefotaxime Based on MIC
Group
Cefotaxime
Totals P Value
S I R
Inpatient 13 1 31 45
< 0.001Outpatient 30 6 9 45
Totals 43 7 40 90
Table 5. Antibiotic Resistance Pattern of Ceftazidime Based on MIC
Group
Ceftazidime
Totals P Value
S I R
Inpatient 12 3 30 45
< 0.001Outpatient 32 5 8 45
Totals 44 8 38 90
2010, the prevalence of ESBLs in inpatients was 64% with a
high incidence of ESBLs in this study for inpatients (25).
Generally, the prevalence of ESBL production is differ-
ent in each region and country due to medical staff’s per-
formance and antibiotic use patterns, infection control
measured in the hospital, and epidemiologic factors. It
seems that the selective pressure exerted by the use of
broad-spectrum antibiotics and the misuse of antibiotics
with the high potential for release of plasmid genes of
group A β-Lactamase (by conjugation) are main factors in
the development of ESBL-producing strains in this region
over time (26, 27). Feizabadi et al. reported the prevalence
of these enzymes as 44.5% and 72.1% in two separate studies
Table 6. Frequency of β-Lactamase OXA-10 Genes and PER in Outpatients and Inpa-
tients
Group Positive Negativ P Value
OXA-10 < 0.001
Inpatient 30 15
Outpatient 4 51
Totals 34 44
PER < 0.001
Inpatient 10 35
Outpatient 1 44
Totals 11 79
Table 7. Frequency of ESBL-Producing Klebsiella spp. Isolates in Outpatients and In-
patients
Group
ESBL
Totals P Value
Positive Negative
Inpatient 30 15 45
< 0.001Outpatient 8 37 45
Totals 38 52 90
in Tehran (28, 29). In South Korea, the prevalence of ESBLs
was 30%, in India, 68%, in Taiwan, 28.4%, and in the United
States, 44% (30-33).In the present study, the frequency of β-
lactamase OXA-10 and PER genes were 66.6% and 8.8%, re-
spectively, in inpatients and 22.2% and 2.2%, respectively, in
outpatients. In previous studies, the frequency of the OXA
gene in Klebsiella and other bacteria from the Enterobac-
teriaceae family was more than PER and their frequency
was higher in inpatients than outpatients. In a study con-
ducted by Jabalameli et al. in 2011, and 112 samples were iso-
lated, the prevalence of β-lactamase genes, including OXA-
10, PER, and VEB was reported as 70%, 50%, and 31%, respec-
tively. This research is consistent with our study for the
prevalence of OXA-10 gene, which is more than PER (34). As
in the study of Farshadzadeh et al. in 2014, the prevalence
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of PER, OXA, and CTX-M genes in 176 isolated strains from
inpatients was 55%, 66% and 1%, respectively (10). In a study
by Luo et al. in 2011, to investigate the prevalence of broad-
spectrum β-lactamases in 59 isolates of Klebsiella, the fre-
quency of OXA, SHV, and CTX-M genes was reported to be
22.1%, 91.5%, and 59.9%, respectively. The prevalence of OXA-
10 gene is lower than that of the present study, which can
be explained by the fact that Luo et al. worked on fewer iso-
lates (35).
The prevalence of PER in bacteria such as Klebsiella and
E. coli is usually as low as in the following studies. How-
ever, the prevalence is much higher in other bacteria such
as Pseudomonas and Acinetobacter. In this regard, in a study
conducted by Shacheraghi et al. in 2010 in Iran, 120 sam-
ples of P. aeruginosa were isolated from burn infections,
which the prevalence of β-lactamase gene PER-1 was re-
ported to be 68% (36), and in another study by Fallah et
al. in 2014 who investigated the prevalence of PER, VEB,
IMP and VIM genes in Iran on 108 isolates of Acinetobac-
ter baumanni, the prevalence of these genes was reported
as 71, 36, 3, and 15%, respectively (37). According to the
current study, the most effective antibiotics for the treat-
ment of UTIs caused by ESBLs-producing Klebsiella strains
are Amikacin and Imipenem.
The reasons for the effectiveness of imipenem may be
low consumption of this antibiotic in the medical staff, its
lack of outpatient use in the community since this antibi-
otic in Iran is a hospital drug and is not prescribed with-
out indication, as well as the absence or low presence of
carbapenemase enzymes in strains related to the family of
Enterobacteriaceae (26, 38, 39). The extensive and arbitrary
use of cephalosporins has led to the proliferation of ESBLs-
producing organisms, which makes these organisms resis-
tant to a wide range of antibiotics from this category. Infec-
tions caused by these resistant microorganisms prolong
the treatment process and increase the length of the hos-
pitalization and increase the risk of death.
5.1. Conclusions
In this study, although a number of strains were resis-
tant to several drug classes, they lacked the β-lactamase
OXA-10 and PER genes. According to numerous studies,
the expression of the ESBL phenotype results from the pro-
duction of broad-spectrum plasmid of group A; therefore,
the difference in the prevalence of positive phenotypes and
negative genotypes should be sought in the presence of
other β-lactamase genes of the group A that cause differ-
ent outbreaks in different regions.
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